Latest news with #BrainSense
Yahoo
31-03-2025
- Business
- Yahoo
Medtronic (NYSE:MDT) TAVR System Shows Strong Five-Year Performance Despite 3% Price Dip
Medtronic recently saw a substantial price movement, climbing 10% over the last quarter. This period was marked by the release of promising five-year data from the Evolut Low Risk Trial, which indicated favorable outcomes for the company's transcatheter aortic valve replacement system compared to surgery. Further boosting investor sentiment was the FDA approval of Medtronic's BrainSense technology, enhancing treatment for Parkinson's disease. Despite challenging overall market conditions, with significant declines in key indexes such as the S&P 500 and Nasdaq, Medtronic's substantial product advancements likely contributed to the positive performance of its shares amidst broader downward trends. Buy, Hold or Sell Medtronic? View our complete analysis and fair value estimate and you decide. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 20 best rare earth metal stocks of the very few that mine this essential strategic resource. Over the past five years, Medtronic has delivered a total shareholder return of 7.52%. While this performance marks a modest increase, it underperforms both the broader U.S. market and the medical equipment industry over the last year, where market returns were 5.8% and industry returns were 2.4%, respectively. Several key developments likely influenced Medtronic's share price trajectory during this period. The announcement of the global observational study DISSECT-N in June 2020 and the FDA approval for the Percept PC Deep Brain Stimulation system marked significant milestones. Furthermore, the launch and European release of the Evolut TAVR system in mid-2020 demonstrated Medtronic's continued commitment to innovation. The company's consistent dividend payouts bolstered investor confidence, with recent approvals maintaining shareholder value. Additionally, the approval and expansion of Medtronic's Renal Denervation technique and the ongoing development of the Hugo soft tissue robotic platform have shaped its growth narrative, targeting increased market share and revenue expansion, particularly in emerging markets. However, challenges such as competitive pressures and regulatory hurdles may have constrained faster growth in the valuation metrics. Collectively, these factors provide context to Medtronic's overall market performance over the past five years. The analysis detailed in our Medtronic valuation report hints at an deflated share price compared to its estimated value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:MDT. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
21-03-2025
- Health
- Yahoo
'Breakthrough' deep brain stimulation device for Parkinson's to make clinical debut
ST. PAUL, Minn., March 21 (UPI) -- Parkinson's disease patients and advocates are marking the start of a new era for treatment of the illness, as a doctors deploy a breakthrough neurological device for the first time in the United States. A team at Stanford University School of Medicine in Palo Alto, Calif., was set to connect two Parkinson's patients to a new type of deep brain stimulation device, or "brain pacemaker," developed by Medtronic Inc., on Friday in a ceremony to hail what they say is the beginning of a new paradigm in long-standing efforts to control sufferers' debilitating tremors. The device, called the BrainSense Adaptive deep brain stimulator, was approved by the Food and Drug Administration on Feb. 24 after a decade of development, testing and trials, and is now poised to make its clinical debut. This brings hopes that, for the first time, a "DBS" device will be able to provide personalized brain neuromodulation in a way that "adapts" to patients' changing needs on an around-the-clock, real-time basis. The procedure will be led by Dr. Helen Bronte-Stewart, the John E. Cahill Family Professor at Stanford Medicine's department of Neurology and Neurological Sciences, who also helmed the clinic trials for the device. She told UPI the occasion will honor the years of "hard work" that went into the development of a device that has the potential to change the everyday reality of Parkinson's sufferers. "The exciting thing is to know that whenever somebody used this device as part of our research trials, they knew it was just for research, that it may not be part of their actual clinical care," Bronte-Stewart said. "Now, once they're on the adaptive DBS, they'll know 'this is it,' it's part of their clinical care and they can stay on it forever." The BrainSense device, in essence, is a "smarter version" of the decades-old deep brain stimulation technology that uses electrical pulses to regulate abnormal brain activity in people with Parkinson's disease. DBS technology, in combination with medication, has helped ease tremors, stiffness and slowed movements for years. However, traditional DBS tech has a downside. It is essentially a "blunt instrument," or a one-size-fits-all solution, pumping out the same level of pulses to electrodes implanted in the brain no matter how a patient's system changes over the course of time, much as cardiac pacemakers once did for the heart. That meant DBS carries too many side effects or is not effective for some patients. But now, also like pacemakers, technological advances allow the devices to individualize their functionality. In the case of Medtronic's new product, it can use a person's individual brain signals to control the electric pulses it delivers in real time, making it much more precise and efficient than older DBS methods. The biggest challenge to overcome was the development of the precise and accurate algorithms needed to make the device work in a safe manner. "A lot of work was put into which inputs to use, which is partly why it took 10 years to develop," Bronte-Stewart said. "You don't want to feed the wrong signal into these automated algorithms because the system is going to adjust itself based on rhythm it's sensing. "That was the big learning curve, just as with the development of smart cardiac pacemakers. What are signals that the algorithms will act off of to go in the right direction?" Another advantage of the new technology is that it will allow for a better balance between the use stimulation and medication to treat Parkinson's tremors. "With continuous DBS, it couldn't adjust accordingly when medication kicks in," she said. "You then have overtreatment, and when the medication wears off, you then have undertreatment. "So, the first way this is going to help is that we'll have a system that measures that brain arrhythmia, and if it senses the medication is doing its work, then the DBS will adjust its amplitude down." In announcing the FDA approval last month, Medtronic called it the largest-ever commercial launch of brain-computer interface technology by several magnitudes. It came after an international study representing the largest and longest assessment of adaptive DBS, an effort led by Stanford, the University of California-San Francisco, Massachusetts General Hospital and Amsterdam University Medical Center. Friday's scheduled initial clinical rollout of the device brought praise from the American Parkinson Disease Association, which called it a major moment in the battle against the disease. "It is incredibly exciting for the [Parkinson's disease] community that this technology is now available clinically, as it has the potential to optimize symptom management to a degree that has not been possible before with standard DBS," APDA chief mission officer Dr. Rebecca Gilbert said in a statement to UPI. "Parkinson's disease and its symptoms can vary quite a bit from person to person, so the more personalized and customized treatment can be to each individual, the better." Gilbert noted existing DBS systems can "make a life-changing difference in my patients who suffer from significant tremors or motor fluctuations." Therefore, she added, "it stands to reason that adaptive DBS would result in better symptom management for each individual, and I am eager to see how that unfolds. "This has the potential to be a game-changer."
Yahoo
25-02-2025
- Health
- Yahoo
FDA approves Medtronic's brain stimulation system for Parkinson's
Medtronic has received approval from the US Food and Drug Administration (FDA) for BrainSense, its adaptive deep brain stimulation (aDBS) therapy for patients living with Parkinson's disease. The approval comes just one month after Medtronic received a CE mark in Europe for the system, which is designed to automatically adjust stimulation for Parkinson's disease patients based on their unique brain activity to address symptoms such as involuntary shaking and balance issues. The medtech giant has also received FDA clearance for the BrainSense Electrode Identifier (EI). Also cleared in Europe, the EI provides a detailed view of the brain signals of Parkinson's patients to help clinicians improve DBS programming and therapy optimisation. Brett Wall, executive vice president and president of Medtronic's neuroscience portfolio, said: 'Medtronic is the only company in the world to offer an aDBS system that dynamically adjusts therapy in real time. 'This new era in Parkinson's care represents more than a decade of intentional innovation – ushering in personalised neuromodulation at a scale that responds to a patient's changing needs, equipping clinicians with unparalleled insights, and setting a new standard for DBS therapy." In 2024, the University of California, San Francisco (UCSF) undertook two studies that tested implants that used aDBS for Parkinson's therapy, with the results published in Nature Communications and Nature Medicine in February and August 2024, respectively. In light of the studies, GlobalData medical device analyst Cynthia Stinchcombe noted that the increasing integration of advanced technology in the management of neurological disorders fitted into the broader industry shift towards precision medicine, a matter further reflected in the FDA's recent push for innovative solutions in Parkinson's disease management. The global neurological devices market is forecast to reach a valuation of $20.9bn by 2033, up from $12.5bn in 2023, according to a report by GlobalData. Other companies developing aDBS systems for addressing Parkinson's disease symptoms include Newronika. This month, the Italian company received an investigational device exemption (IDE) from the FDA for AlphaDBS, paving the way for the initiation of a pivotal trial of the system in the US. In addition, the company completed a €13.6m ($14.1m) Series B funding round to support the system's further development. "FDA approves Medtronic's brain stimulation system for Parkinson's" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
